Floatz logo

Ifinatamab Deruxtecan

Prostate Cancer

Merck Sharp & Dohme LLCantibody_drug_conjugatePhase 3Active
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
59/ 100

Competitive context

513 Active assets in the Prostate Cancer cohort.

Asset / SponsorPhaseRating
Avodart
Bay State Clinical Trials, Inc.
Phase 4BBB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
Degarelix
Bayer
Phase 4BBB
PROPOFOL
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
AVOLVE
Masonic Cancer Center, University of Minnesota
Phase 4BB

View all 50 →

Same molecule, other indications

Ifinatamab Deruxtecan is also rated in:

small cell lung carcinomaDormant
B
Indicative ·
60 / 100
View asset →
prostate neoplasmDormant
CCC
Indicative ·
54 / 100
View asset →
Recurrent or Metastatic Solid TumorsDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →